According to Vision Research Reports, the global antimicrobial resistance diagnostics market size is expected to hit around USD 7.3 billion by 2030 and registering growth at a CAGR of 8.51% from 2022 to 2030.
According to Vision Research Reports, the global antimicrobial resistance diagnostics market size is expected to hit around USD 7.3 billion by 2030 and registering growth at a CAGR of 8.51% from 2022 to 2030.
The growth of the antimicrobial resistance diagnostics market is attributed to the increased risk of developing drug-resistant bacterial infections, the introduction of novel technologies, and increasing government initiatives to diagnose & reduce AMR infections. To address the global health challenge of AMR, government bodies such as the U.S. FDA support the development of next-generation sequencing-based diagnostic tests to identify the right pathogen to help healthcare providers to treat infections more accurately.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/39711
Increasing adoption of point of care and rapid testing for drug-resistant microbial infections is expected to fuel the market growth in the forecast period. PCR technology-based POC tests are expected to control the progression of hospital-acquired infections (HAIs) in healthcare facilities. Moreover, key market players such as Abbott, F. Hoffmann-La Roche Ltd, and others have a strong product portfolio of rapid diagnostic tests for multiple drug-resistant infections. Moreover, increasing involvement of government and non-government bodies such as the AMR Industry Alliance is helping to build strategies to support diagnostic development to reduce antimicrobial resistance.
The AMR diagnostics market is segmented based on technology, pathogen, and end-user. Among the technology segment, the polymerase chain reaction segment held the largest share in 2021 and is expected to maintain its dominance through the forecast period. High penetration of PCR technology and advancements in the technology has increased the segment share. Moreover, the high adoption rate of PCR tests for HAIs such as c. difficile and MRSA is further driving segment growth. However, the rapid & point of care segment is anticipated to grow at the fastest rate in the forecast period.
North America is the largest market for antimicrobial resistance diagnostics. The high risk of developing AMR infections, developed healthcare infrastructure, favorable healthcare policies, and presence of key market players in the region have increased the market share. According to an article published by CDC in August 2022, in the U.S., around 2.8 million people are diagnosed with antibiotic-resistant infections each year. MRSA and c.difficile are major prevalent infections reported in the U.S. However, the Asia Pacific is expected to grow at the fastest rate during the forecast period. The growth of the region can be attributed to the increasing adoption of novel diagnostic techniques, improving healthcare policies, and increasing awareness among people is expected to fuel the segment growth in the region.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 3.5 billion |
| Revenue Forecast by 2030 | USD 7.3 billion |
| Growth rate from 2022 to 2030 | CAGR of 8.51% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Technology, Pathogen, End-User, Region |
| Companies Covered | F. Hoffmann-La Roche, Ltd., Abbott, BD, Danaher, and Accelerate Diagnostics, Inc. |
Market Dynamics
Driver: Rising incidence of infectious diseases coupled with epidemic & pandemic events
The growing number of epidemic outbreaks caused by infectious pathogens such as Haemophilus influenzae, Neisseria meningitides, Streptococcus pneumoniae, Shigella, Vibrio cholera, Neisseria gonorrhoeae, and Salmonella serotype Typhi is also propelling the demand for antimicrobial susceptibility testing products. Listed below are statistics regarding the increased incidence of several major infectious diseases in recent years:
- According to the WHO, TB is one of the top 10 causes of death and the leading cause of a single infectious agent. In 2018, 10 million people across the globe were estimated to be suffering from tuberculosis, of which 1.5 million people died due to the disease.
- According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), globally, 1.7 million people were newly infected with HIV in 2019, 38 million people are living with HIV, and 690 thousand people died of AIDS-related illnesses.
- According to the World Malaria Report 2019, an estimated 228 million cases of malaria were diagnosed worldwide. The report further stated that the nineteen countries in sub-Saharan Africa and India carried almost 85% of the global malaria burden.
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39711
Restraint: High cost of automated ID/AST systems
Automated antimicrobial susceptibility testing instruments are equipped with highly advanced features and functionalities and are priced at premium rates. The use of automated AST systems reduces the incubation and detection time. However, the high cost of these systems is a major restraining factor for their widespread adoption by end-users, especially for small-budget institutions.
Opportunity: Awareness initiatives for antimicrobial resistance and its control
Antimicrobial susceptibility tests play a significant role in detecting the resistance of bacteria to antibiotics. Healthcare authorities are increasingly becoming aware of the significance of antimicrobial susceptibility to ensure the efficacy and safety of AST methods. Various initiatives—for instance, the Global Sepsis Alliance (GSA), a non-profit organization located in the US, works to support over one million caregivers in more than 70 countries and increase awareness about sepsis and its management. Likewise, in the US, the CDC launched a new website, Antibiotic / Antimicrobial Resistance (AR / AMR), to increase AMR awareness and support the early recognition, diagnosis, and treatment of antibiotic resistance. Along with this, various local government and intergovernmental organizations such as the WHO, EU, Transatlantic Task Force on Antimicrobial Resistance (TATFAR), and Global Health Security Agenda (GHSA) are developing and implementing plans and efforts to tackle antimicrobial resistance.
Challenge: Complex regulatory frameworks that delay antimicrobial testing approvals
Among the major challenges faced by the AST market is the time lapse between establishing clinical breakpoints, approval of new antimicrobial agents, and the inclusion of these agents in antimicrobial susceptibility testing. The FDA establishes these breakpoints when drug manufacturers submit individual new drug applications or when device manufacturers submit requests to revise the breakpoints. Furthermore, the unavailability of clinical breakpoints for certain drugs is also limiting the adoption of AST products.
Key Players
- F. Hoffmann-La Roche, Ltd.
- Abbott
- BD
- Danaher
- Accelerate Diagnostics, Inc.
Market Segmentation
- By Technology
- Microbiology Culture
- Immunoassay
- PCR
- NGS
- Mass Spectrometry
- Rapid & Point of Care
- Others
- By Pathogen
- Drug Resistant Streptococcus Pneumoniae (DRSP)
- Drug Resistant Campylobacter (DRC)
- Clostridium Difficile (CD)
- Methicillin Resistant Staphylococcus Aureus (MRSA)
- Drug Resistant Neisseria Gonorrhoeae (DRNG)
- Drug Resistant Salmonella (DRNTS)
- Others
- By End-User
- Hospitals
- Diagnostic Laboratories
- Pharmaceutical & Biotechnology Companies
- Others
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Click Here to View Full Report Table of Contents
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39711
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333